Impact of HIV co-infection on the evolution and transmission of multidrug-resistant tuberculosis

eLife

Volumn 5, Issue AUGUST, 2016, Pages

  Eldholm, Vegard ^a   Rieux, Adrien ^b   Monteserin, Johana ^c,d   Julia Montana, Lopez ^b   Palmero, Domingo ^e   Lopez, Beatriz ^c,d   Ritacco, Viviana ^c,d   Didelot, Xavier ^f   Balloux, Francois ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e HOSPITAL F J MUÑIZ   (Argentina)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; KATG PROTEIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SIMULATION; DISEASE TRANSMISSION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHYLOGENY; SINGLE NUCLEOTIDE POLYMORPHISM; COMPLICATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; SOUTH AMERICA; TRANSMISSION; TUBERCULOSIS, MULTIDRUG-RESISTANT; WESTERN HEMISPHERE;

AMERICAS; ANTITUBERCULAR AGENTS; COINFECTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HIV INFECTIONS; HUMANS; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; SOUTH AMERICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84983087044     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.16644.001     Document Type: Article

References (50)

1. Biek R, Pybus OG, Lloyd-Smith JO, Didelot X. 2015. Measurably evolving pathogens in the genomic era. Trends in Ecology & Evolution 30: 306-313. doi: 10.1016/j.tree.2015.03.009
2. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. 1996. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. The Lancet 348: 928-931. doi: 10.1016/S0140-6736(96)03027-9
3. Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR. 2013. Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa. PLoS One 8: e73975. doi: 10.1371/journal.pone.0073975
4. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W, Tuberculosis Trials Consortium. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. American Journal of Respiratory and Critical Care Medicine 173: 350-356. doi: 10. 1164/rccm.200503-417OC
5. Burman WJ, Gallicano K, Peloquin C. 1999. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clinical Infectious Diseases 28: 419-429. doi: 10.1086/515174
6. Carey V, Long L, Gentleman R. 2016. RBGL: An interface to the BOOST graph library. R package version 1.44.0. Bioconductor.
7. Cauchemez S, Carrat F, Viboud C, Valleron AJ, Boëlle PY. 2004. A bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Statistics in Medicine 23: 3469-3487. doi: 10.1002/sim.1912
8. Centers for Disease Control and Prevention. 1998. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Morbidity and Mortality Weekly Report 47: 1-58.
9. Chum HJ, O’Brien RJ, Chonde TM, Graf P, Rieder HL. 1996. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 10: 299-310. doi: 10.1097/00002030-199603000-00009
10. Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, et al. 2015. Evolution of extensively drug-resistant tuberculosis over Four decades: whole genome sequencing and dating analysis of mycobacterium tuberculosis Isolates from kwaZulu-natal. PLoS Medicine 12: e1001880. doi: 10.1371/journal.pmed.1001880
11. Didelot X, Eyre DW, Cule M, Ip CL, Ansari MA, Griffiths D, Vaughan A, O’Connor L, Golubchik T, Batty EM, Piazza P, Wilson DJ, Bowden R, Donnelly PJ, Dingle KE, Wilcox M, Walker AS, Crook DW, Peto TE, Harding RM. 2012. Microevolutionary analysis of clostridium difficile genomes to investigate transmission. Genome Biology 13: R118. doi: 10.1186/gb-2012-13-12-r118
12. Didelot X, Gardy J, Colijn C. 2014. Bayesian inference of infectious disease transmission from whole-genome sequence data. Molecular Biology and Evolution 31: 1869-1879. doi: 10.1093/molbev/msu121
13. Didelot X, Nell S, Yang I, Woltemate S, van der Merwe S, Suerbaum S. 2013. Genomic evolution and transmission of helicobacter pylori in two South African families. PNAS 110: 13880-13885. doi: 10.1073/pnas. 1304681110
14. Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. 2016. Within-host evolution of bacterial pathogens. Nature Reviews Microbiology 14: 150-162. doi: 10.1038/nrmicro.2015.13
15. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evolutionary Biology 7: 214. doi: 10.1186/1471-2148-7-214
16. Eldholm V, Monteserin J, Rieux A, Lopez B, Sobkowiak B, Ritacco V, Balloux F. 2015. Four decades of transmission of a multidrug-resistant mycobacterium tuberculosis outbreak strain. Nature Communications 6 7119. doi: 10.1038/ncomms8119
17. Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsåker T, Mengshoel AT, Dyrhol-Riise AM, Balloux F. 2014. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biology 15: 490. doi: 10.1186/s13059-014-0490-3
18. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Böttger EC, Egger M, Swiss HIV Cohort Study, Molecular epidemiology of tuberculosis study group. 2012. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. Journal of Clinical Microbiology 50: 388-395. doi: 10.1128/JCM.05392-11
19. Girardi E, Sabin CA, d’Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA, Antiretroviral Therapy Cohort Collaboration. 2005. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases 41: 1772-1782. doi: 10.1086/498315
20. Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L, Pedrazzoli D, Pozniak A, Abubakar I, Delpech V, Lipman M. 2015. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. The Lancet HIV 2: e243-e251. doi: 10.1016/S2352-3018(15)00063-6
21. Kwan CK, Ernst JD. 2011. HIV and tuberculosis: a deadly human syndemic. Clinical Microbiology Reviews 24: 351-376. doi: 10.1128/CMR.00042-10
22. Lawn SD, Badri M, Wood R. 2005. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19: 2109-2116. doi: 10.1097/01.aids.0000194808. 20035.c1
23. Lawn SD, Wood R. 2005. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clinical Infectious Diseases 41: 1783-1786. doi: 10.1086/498308
24. Lekone PE, Finkenstädt BF. 2006. Statistical inference in a stochastic epidemic SEIR model with control intervention: Ebola as a case study. Biometrics 62: 1170-1177. doi: 10.1111/j.1541-0420.2006.00609.x
25. Li J, Munsiff SS, Driver CR, Sackoff J. 2005. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clinical Infectious Diseases 41: 83-91. doi: 10.1086/430377
26. Lukoye D, Cobelens FG, Ezati N, Kirimunda S, Adatu FE, Lule JK, Nuwaha F, Joloba ML. 2011. Rates of anti-tuberculosis drug resistance in kampala-uganda are low and not associated with HIV infection. PLoS One 6: e16130. doi: 10.1371/journal.pone.0016130
27. Ma M-J, Yang Y, Wang H-B, Zhu Y-F, Fang L-Q, An X-P, Wan K-L, Whalen CC, Yang X-X, Lauzardo M, Zhang Z-Y, Cao J-F, Tong Y-G, Dai E-H, Cao W-C. 2015. Transmissibility of tuberculosis among school contacts: An outbreak investigation in a boarding middle school, China. Infection, Genetics and Evolution 32: 148-155. doi: 10.1016/j.meegid.2015.03.001
28. McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. 2014. Mutation rate and the emergence of drug resistance in mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 69: 292-302. doi: 10.1093/jac/dkt364
29. Meyssonnier V, Veziris N, Bastian S, Texier-Maugein J, Jarlier V, Robert J. 2012. Increase in primary drug resistance of mycobacterium tuberculosis in younger birth cohorts in France. Journal of Infection 64: 589-595. doi: 10.1016/j.jinf.2012.01.013
30. Patel KB, Belmonte R, Crowe HM. 1995. Drug malabsorption and resistant tuberculosis in HIV-infected patients. New England Journal of Medicine 332: 336-337. doi: 10.1056/NEJM199502023320518
31. Peloquin CA, MacPhee AA, Berning SE. 1993. Malabsorption of antimycobacterial medications. New England Journal of Medicine 329: 1122-1123. doi: 10.1056/NEJM199310073291513
32. Porco TC, Oh P, Flood JM. 2013. Antituberculosis drug resistance acquired during treatment: An analysis of cases reported in California, 1994-2006. Clinical Infectious Diseases 56: 761-769. doi: 10.1093/cid/cis989
33. Pybus OG, Rambaut A. 2009. Evolutionary analysis of the dynamics of viral infectious disease. Nature Reviews Genetics 10: 540-550. doi: 10.1038/nrg2583
34. Reves R, Blakey D, Snider DE, Farer LS. 1981. Transmission of multiple drug-resistant tuberculosis: report of a school and community outbreak. American Journal of Epidemiology 113: 423-435.
35. Ritacco V, Di Lonardo M, Reniero A, Ambroggi M, Barrera L, Dambrosi A, Lopez B, Isola N, de Kantor IN. 1997. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. Journal of Infectious Diseases 176: 637-642. doi: 10.1086/514084
36. Robert J, Trystram D, Truffot-Pernot C, Jarlier V. 2003. Multidrug-resistant tuberculosis: eight years of surveillance in France. European Respiratory Journal 22: 833-837. doi: 10.1183/09031936.03.00014103
37. Sergeev R, Colijn C, Murray M, Cohen T. 2012. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Science Translational Medicine 4: 135ra67. doi: 10.1126/scitranslmed.3003815
38. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. 2014. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. American Journal of Epidemiology 179: 216-225. doi: 10.1093/aje/kwt246
39. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK. 1993. Exogenous reinfection with multidrug-resistant mycobacterium tuberculosis in patients with advanced HIV infection. New England Journal of Medicine 328: 1137-1144. doi: 10.1056/NEJM199304223281601
40. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. 2009. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infectious Diseases 9: 91. doi: 10.1186/1471-2334-9-91
41. Storla DG, Yimer S, Bjune GA. 2008. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 8: 15. doi: 10.1186/1471-2458-8-15
42. Suchindran S, Brouwer ES, Van Rie A. 2009. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 4: e5561. doi: 10.1371/journal.pone.0005561
43. Waisman JL, Palmero DJ, Alberti FA, Güemes Gurtubay JL, Francos JL, Negroni R. 2001. Improved prognosis in HIV/AIDS related multi-drug resistant tuberculosis patients treated with highly active antiretroviral therapy. Medicina 61: 810-814.
44. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 2007. HIV Infection and multidrug-resistant tuberculosis-The perfect storm. Journal of Infectious Diseases 196: S86-S107. doi: 10. 1086/518665
45. Whittles LK, Didelot X. 2016. Epidemiological analysis of the eyam plague outbreak of 1665-1666. Proceedings of the Royal Society 283: 20160618. doi: 10.1098/rspb.2016.0618
46. Worby CJ, Lipsitch M, Hanage WP. 2014. Within-host bacterial diversity hinders accurate reconstruction of transmission networks from genomic distance data. PLoS Computational Biology 10: e1003549. doi: 10.1371/journal.pcbi.1003549
47. World Health Organization. 2013. Global report: UNAIDS report on the global AIDS epidemic.
48. World Health Organization. 2015. Global Tuberculosis Report.
49. Yang Z. 2007. PAML 4: Phylogenetic analysis by maximum likelihood. Molecular Biology and Evolution 24: 1586-1591. doi: 10.1093/molbev/msm088
50. Zerbini E, Chirico MC, Salvadores B, Amigot B, Estrada S, Algorry G. 2008. Delay in tuberculosis diagnosis and treatment in four provinces of Argentina. The International Journal of Tuberculosis and Lung Disease 12: 63-68.